Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.

Dedee Frances MurrellA PatsatsiP StavropoulosS BaumT ZeeliJ S KernA-V Roussaki-SchulzeR SinclairI D BassukasD ThomasA NealeP AroraF CauxVictoria P WerthS G GourlayP Jolynull null

Published in: The British journal of dermatology (2021)

Rilzabrutinib alone, or with much lower CS doses than usual, was safe, with rapid clinical activity in pemphigus vulgaris. These data suggest that BTK inhibition may be a promising treatment strategy and support further investigation of rilzabrutinib for the treatment of pemphigus.

Keyphrases

phase ii
clinical trial
open label
randomized controlled trial
tyrosine kinase
electronic health record
big data
machine learning
artificial intelligence
deep learning
quantum dots
placebo controlled